source
- Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitabilityGenetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
- FDA unveils Global Reliance Disclosure Program to speed international drug approvalsThe FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…